You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
Bertagnolli’s burgeoning NIH agenda
Monica Bertagnolli is just two months into directing the $48 billion NIH, but she has a laundry list of challenges ahead of her. The agency is staring down potential budget cuts, ongoing interrogations of its infectious disease work, and a balancing act with advocates pressing for price controls on federally-funded drugs.
The veteran oncologist and former NCI director sat down with STAT in a far-ranging interview to discuss her priorities and those battles ahead. Bertagnolli said she welcomes the scrutiny of controversial infectious disease studies and questions about whether the agency has made any progress on long Covid, but also defended NIAID’s work amid ratcheting Republican demands for better oversight and even bans on gain-of-function research.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect